FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: AREV Life Sciences Global Corp. (the "Issuer").

Trading Symbol: AREV

Date: August 17, 2022

1. New Options Granted:

Date of Grant: August 17, 2022

| Name of Optionee | Position (Director/ Officer/ Employee/ Consultant/ Management Company | Insider Yes or No? | No. of Optioned Shares | Exercise Price | Expiry Date | No. of Options Granted in Past 12 Months |
|------------------|---|--------------------------|------------------------------|-------------------|--------------------|---|
| Sateesh Apte | Consultant | No | 100,000 | \$0.12 | August 17, 2027 | 0 |
| | | | | | | |

Total Number of optioned shares proposed for acceptance: 100,000

2. Other Presently Outstanding Options:

| Name of Optionee | No. of Optioned Shares ⁽¹⁾ | Exercise Price | Original Date of Grant | Expiry Date | |
|---|--|-------------------|---------------------------|-------------------|--|
| Denby Greenslade | 16,667 | \$0.40 | Sept. 14, 2018 | Sept. 14, 2023 | |
| Denby Greenslade | 16,667 | \$0.325 | May 2, 2019 | May 2, 2024 | |
| Efficacy Technologies Inc. | 8,333 | \$0.26 | June 10, 2019 | June 10, 2024 | |
| Michael Nen | 16,667 | \$0.26 | June 10, 2019 | June 10, 2024 | |
| Denby Greenslade | 100,000 | \$0.15 | December 14, 2020 | December 14, 2025 | |
| Efficacy Technologies Inc. | 100,000 | \$0.15 | December 14, 2020 | December 14, 2025 | |
| Dr. Robert Melamede | 50,000 | \$0.31 | January 19, 2021 | January 19, 2026 | |
| Global Health & Hygiene Solutions, LLC | 50,000 | \$0.275 | February 2, 2021 | February 2, 2026 | |
| Roscoe Moore | 150,000 | \$0.31 | February 9, 2021 | February 9, 2026 | |
| Jay Noller | 100,000 | \$0.302 | February 19, 2021 | February 19, 2026 | |
| Harold Smith | 150,000 | \$0.17 | June 1, 2021 | June 1, 2026 | |
| Kevin Phelps | 100,000 | \$0.185 | June 10, 2021 | June 10, 2026 | |
| Kevin Phelps | 50,000 | \$0.12 | November 8, 2021 | November 8, 2026 | |
| Melvin Maxwell | 150,000 | \$0.12 | November 8, 2021 | November 8, 2026 | |
| Denby Greenslade | 150,000 | \$0.12 | November 8, 2021 | November 8, 2026 | |
| Chiron Capital Inc. | 250,000 | \$0.12 | November 8, 2021 | November 8, 2026 | |
| Allan Echino | 150,000 | \$0.31 | December 23, 2021 | December 23, 2026 | |
| Brian Thomas | 25,000 | \$0.31 | December 23, 2021 | December 23, 2026 | |
| Navin Sandhu | 50,000 | \$0.33 | January 18, 2022 | January 18, 2027 | |
| Tara Byrd | 50,000 | \$0.33 | January 18, 2022 | January 18, 2027 | |
| Ron Cooper | 100,000 | \$0.33 | January 18, 2022 | January 18, 2027 | |
| Douglas Sorocco | 100,000 | \$0.29 | February 17, 2022 | February 17, 2027 | |
| Brian Elliott | 100,000 | \$0.22 | April 19, 2022 | April 19, 2027 | |

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held: June 29, 2018
- (b) State the date of the news release announcing the grant of options: August 17, 2022
- (c) State the total issued and outstanding share capital at the date of grant or amendment: 30,367,141
- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options: 10%
- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan: 853,381
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors: N/A
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer: N/A

Certificate of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated August 17, 2022

| MIKE WITHROW |
|----------------------------|
| Name of Director or Senior |
| Officer |
| |
| <u>"Mike Withrow"</u> |
| Signature |
| _ |
| DIRECTOR |
| Official Capacity |